Alvotech Q4 2025 and Full Year 2025 Financial Results
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) reported Q4 2025 revenues of $173M (+13% YoY) and FY 2025 revenues of $593M (+21% YoY). Adjusted EBITDA was $69M in Q4 and $137M for FY 2025 (+27% YoY). Cash on Dec 31, 2025 was $172M. Multiple biosimilar approvals and commercial deals were announced; management reaffirmed 2026 guidance of $650–700M revenue and $180–220M adjusted EBITDA.
Company cited regulatory observations from an FDA inspection and plans to resubmit affected applications in Q2 2026 while expanding partnerships and acquisitions.
Positive
- FY revenue +21% YoY to $593M
- Adjusted EBITDA +27% YoY to $137M
- Cash balance of $172M at Dec 31, 2025
- Three new biosimilars approved in multiple markets
- Selarsdi (Stelara biosimilar) launched in the US by partner Teva
- Raised ~ $300M from capital markets and Nasdaq Stockholm listing
Negative
- FDA inspection observations at Reykjavik facility require corrective actions and resubmission
- 2026 revenue downside acknowledged: lower guidance assumes no US launch contributions
- Dependence on partners for commercial reach may delay or limit direct US revenues
News Market Reaction – ALVO
In the Mar 19 session, ALVO declined 5.79%, reflecting a notable negative market reaction. Argus tracked a trough of -3.7% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 04 | Conference participation | Neutral | -4.0% | Participation in Morgan Stanley healthcare conference with investor meetings and webcast. |
| May 08 | Regulatory pipeline update | Positive | +18.1% | MHRA acceptance of AVT23 marketing application referencing Xolair for allergy indications. |
| May 07 | Q1 2025 earnings beat | Positive | +18.1% | Strong Q1 2025 results with major revenue growth and raised full‑year guidance. |
| May 05 | Acquisition announcement | Positive | -4.3% | Acquisition of Xbrane’s R&D operations and XB003 biosimilar candidate in Sweden. |
| May 02 | Earnings webcast notice | Neutral | +3.5% | Scheduling of Q1 2025 results release and accompanying investor conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tagged earnings/financial updates have often coincided with sizeable moves, frequently positive, though strategic M&A has seen at least one negative reaction.
Recent tagged events for Alvotech include Q1 2025 results on May 7, 2025, where revenue reached $132.8M and full‑year guidance rose to $600–700M with $200–280M adjusted EBITDA, driving a strong positive reaction. Earlier in May 2025, the company announced acquiring Xbrane’s R&D operations and highlighted $1.9B invested in biosimilars, which drew a negative move. Conference participation and webcast notices have produced smaller, generally positive reactions.
Key Terms
form 6-k regulatory
ifrs regulatory
adjusted ebitda financial
biosimilar medical
biologics license applications regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
REYKJAVIK, Iceland, March 18, 2026 (GLOBE NEWSWIRE) --
Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB)
Financial Highlights
A supplemental long‑form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar The supplemental document is provided solely for reference and is not part of this SEC Form 6‑K. The Form 6‑K should not be read together with, or construed as referring to, the supplemental long‑form release.
Q4 2025 Highlights
- Total revenues1 were
$173 million , up13% Year-on-Year (YoY) - Adjusted EBITDA1 was
$69 million with Gross Margin at66% - AVT05 was approved as a biosimilar to Simponi® in the UK and European Economic Area (EEA)
- AVT03 was approved as a biosimilar to Prolia® and Xgeva® in the EEA
- The EMA accepted for review a marketing application for AVT23, referencing Xolair®
- After the end of the quarter, Alvotech entered into supply and commercialization agreements with Sandoz, covering multiple biosimilars candidates in Canada, Australia and New Zealand
FY 2025 Highlights
- Total revenues1 were
$593 million , up21% YoY - Adjusted EBITDA1 was
$137 million , up27% YoY, with Gross Margin at61% - The cash balance on December 31, 2025, was
$172 million - Second biosimilar in the US, Selarsdi™ referencing Stelara® launched by commercial partner Teva
- Three new biosimilars were approved in multiple markets, including the UK, EEA and Japan
- Alvotech acquired Xbrane’s R&D organization in Sweden and Ivers-Lee Group in Switzerland
- The company listed its shares on Nasdaq Stockholm and raised new equity
- Linda Jonsdottir was appointed Chief Financial Officer, Dr. Balaji V. Prasad was appointed Chief Strategy Officer, while Joseph McClellan transitioned into the role of Chief Operating Officer and Anthony Maffia into the role of Chief Regulatory and Quality Officer
________________________________
1 Figures are adjusted to exclude items that are not indicative of our ongoing operating performance. Please see the disclaimer on ‘Non IFRS Financial Measures’ at the end of this press release. As a foreign private issuer, Alvotech is not required to, and does not, prepare or file quarterly financial statements under IFRS or with the SEC. The financial information included in this Form 6-K reflects management’s current estimates and is presented for the purpose of providing an interim business update.
Comments by Chairman of the Board and Outgoing CEO, Róbert Wessman:
“Last year we continued to expand our dedicated end-to-end biosimilars platform, advancing our pipeline with the launches of three newly approved biosimilars, expanding our R&D operation and adding a centralized assembly and packaging unit through acquisitions, while also strengthening our global network through new commercial partnerships.
“We now have five approved and on-market biosimilars supported by our global partners which provide Alvotech with commercial reach into 90 countries worldwide. We have an industry leading pipeline of 30 biosimilars in development and continue adding to it at an accelerated pace.
“During the year we further strengthened our financial position, raising close to
“At the same time, we addressed the regulatory observations following the FDA inspection of our Reykjavik manufacturing facility and we implemented a comprehensive improvement program. Based on the progress made so far, we expect to resubmit the affected applications to the FDA during the second quarter of 2026. We have addressed regulatory observations before, and we know how to resolve them. Our focus has been on strengthening the operational platform so that we can continue to scale the business globally.
“We have strengthened the leadership team, with Lisa Graver’s appointment as Chief Executive Officer, and all the key management of the company is now located onsite in Iceland. Lisa and I have worked together for over twenty years, and she is ideally positioned to lead the company through this next stage. She knows the company very well, having been a board member since 2022, which gives her a deep understanding of our strategy, our platform and our global partnerships.
“As Executive Chairman of the Board I will continue to be actively engaged in the business, and I am looking forward working closely with Lisa and the leadership team as we continue building Alvotech into a leading biosimilars company.”
Outlook for 2026
Management reaffirms its outlook for 2026. With continued focus on robust cash flow and margin expansion by delivering solid sales growth and driving operational efficiencies across the company, management anticipates total revenues in the range of
Alvotech anticipates receiving U.S. approval by late 2026 for four Biologics License Applications from the U.S. Food and Drug Administration, with minimal impact on the topline. The lower end of the revenue range assumes no revenues from new launches into the U.S. market in 2026.
Invitation to Q4 2025 and Full Year 2025 management presentation:
Join us to listen to the live audio webcast at 8:00 AM EST (12:00 GMT, 13:00 CET) on Thursday, March 19, 2026.
The audio webcast will be accessible via the following link:
https://edge.media-server.com/mmc/p/u2p8ged8/
To participate via telephone in the Q&A session, please register using this link to obtain your PIN:
https://register-conf.media-server.com/register/BI1c565f9bbee94c928c676ea73f178077
Presentation slides for the webcast and other materials are available on the company’s website: https://investors.alvotech.com/earnings-calendar
For further information, please contact:
Media – alvotech.media@alvotech.com
Benedikt Stefansson
Sarah MacLeod
Investors - alvotech.ir@alvotech.com
Dr. Balaji V Prasad (US)
Patrik Ling (SE)
Benedikt Stefansson (IS)
The information was submitted for publication through the agency of the contact persons.
Financial calendar:
Annual or interim results will be released on the dates specified below, after the close of U.S. markets. An earnings call is held on the following day, after release of the results. Please note that all dates are subject to change.
| Quarter | Date of release | Date of earnings call |
| Q1 2026 | May 6, 2026 | May 7, 2026 |
| Q2 2026 | August 19, 2026 | August 20, 2026 |
| Q3 2026 | November 11, 2026 | November 12, 2026 |
| Q4 2026 | March 10, 2027 | March 11, 2027 |
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.
Forward Looking Statements
Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.
Non IFRS Financial Measures
This Presentation may include projections of certain financial measures not presented in accordance with International Financial Reporting Standards (“IFRS”) including, but not limited to, Adjusted Revenues, EBITDA and certain ratios and other metrics derived therefrom. These non-IFRS financial measures are not measures of financial performance in accordance with IFRS and may exclude items that are significant in understanding and assessing the Company’s financial results. Therefore, these measures should not be considered in isolation or as an alternative to net income, cash flows from operations or other measures of profitability, liquidity or performance under IFRS. You should be aware that the Company’s presentation of these measures may not be comparable to similarly-titled measures used by other companies. The Company believes these non-IFRS measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. The Company believes that the use of these non-IFRS financial measures provide an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company’s financial measures with other similar companies, many of which present similar non-IFRS financial measures to investors. These non-IFRS financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-IFRS financial measures. Due to the high variability and difficulty in making accurate forecasts and projections of some of the information excluded from these projected measures, together with some of the excluded information not being ascertainable or accessible, the Company is unable to quantify certain amounts that would be required to be included in the most directly comparable IFRS financial measures without unreasonable effort. Consequently, no disclosure of estimated comparable IFRS measures is included and no reconciliation of the forward-looking non-IFRS financial measures is included. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.
